BR0011116A - Usos de uma nsaid que libera no como um sal farmaceuticamente aceitável ou um enanciÈmero do mesmo, e de uma nsaid que libera no e de um inibidor de bomba de próton suscetìvel a ácido ou um sal do mesmo ou um enanciÈmero ou de um sal do enanciÈmero, método para o tratamento de uma infecção bacteriana, e, formulação farmacêutica adequada para uso no tratamento de infecções bacterianas - Google Patents

Usos de uma nsaid que libera no como um sal farmaceuticamente aceitável ou um enanciÈmero do mesmo, e de uma nsaid que libera no e de um inibidor de bomba de próton suscetìvel a ácido ou um sal do mesmo ou um enanciÈmero ou de um sal do enanciÈmero, método para o tratamento de uma infecção bacteriana, e, formulação farmacêutica adequada para uso no tratamento de infecções bacterianas

Info

Publication number
BR0011116A
BR0011116A BR0011116-3A BR0011116A BR0011116A BR 0011116 A BR0011116 A BR 0011116A BR 0011116 A BR0011116 A BR 0011116A BR 0011116 A BR0011116 A BR 0011116A
Authority
BR
Brazil
Prior art keywords
salt
treatment
nsaid
releases
enancièmero
Prior art date
Application number
BR0011116-3A
Other languages
English (en)
Inventor
Arne Eek
Johan Raud
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9902027A external-priority patent/SE9902027D0/xx
Priority claimed from SE9904704A external-priority patent/SE9904704D0/xx
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR0011116A publication Critical patent/BR0011116A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"USOS DE UMA NSAID QUE LIBERA NO COMO UM SAL FARMACEUTICAMENTE ACEITáVEL OU UM ENANCIÈMERO DO MESMO, E DE UMA NSAID QUE LIBERA NO E DE UM INIBIDOR DE BOMBA DE PRóTON SUSCETìVEL A ACIDO OU UM SAL DO MESMO OU UM ENANCIÈMERO OU DE UM SAL DO ENANCIÈMERO, MéTODO PARA O TRATAMENTO DE UMA INFECçãO BACTERIANA, E, FORMULAçãO FARMACêUTICA ADEQUADA PARA USO NO TRATAMENTO DE INFECçõES BACTERIANAS". A presente invenção descreve o uso de NSAIDS que liberam NO, especialmente NSAIDS que liberam NO de fórmula (1) ou um sal ou enanciómero farmaceuticamente aceitável das mesmas, para a manufatura de um medicamento para o tratamento de infecções bacterianas, especialmente causadas ou mediadas por Helicobacter pylori. é também descrito o uso de uma NSAID que libera NO em combinação com um inibidor de bomba de próton suscetível a ácido para o tratamento de infecções bacterianas.
BR0011116-3A 1999-06-01 2000-05-25 Usos de uma nsaid que libera no como um sal farmaceuticamente aceitável ou um enanciÈmero do mesmo, e de uma nsaid que libera no e de um inibidor de bomba de próton suscetìvel a ácido ou um sal do mesmo ou um enanciÈmero ou de um sal do enanciÈmero, método para o tratamento de uma infecção bacteriana, e, formulação farmacêutica adequada para uso no tratamento de infecções bacterianas BR0011116A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9902027A SE9902027D0 (sv) 1999-06-01 1999-06-01 New use
SE9904704A SE9904704D0 (sv) 1999-12-21 1999-12-21 New use
PCT/SE2000/001071 WO2000072838A1 (en) 1999-06-01 2000-05-25 New use of compounds as antibacterial agents

Publications (1)

Publication Number Publication Date
BR0011116A true BR0011116A (pt) 2002-02-19

Family

ID=26663588

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0011116-3A BR0011116A (pt) 1999-06-01 2000-05-25 Usos de uma nsaid que libera no como um sal farmaceuticamente aceitável ou um enanciÈmero do mesmo, e de uma nsaid que libera no e de um inibidor de bomba de próton suscetìvel a ácido ou um sal do mesmo ou um enanciÈmero ou de um sal do enanciÈmero, método para o tratamento de uma infecção bacteriana, e, formulação farmacêutica adequada para uso no tratamento de infecções bacterianas

Country Status (27)

Country Link
US (2) US6593339B1 (pt)
EP (1) EP1196155B1 (pt)
JP (1) JP4818516B2 (pt)
KR (1) KR100671392B1 (pt)
CN (1) CN1165298C (pt)
AR (1) AR024159A1 (pt)
AT (1) ATE272396T1 (pt)
AU (1) AU780678B2 (pt)
BG (1) BG106158A (pt)
BR (1) BR0011116A (pt)
CA (1) CA2373653C (pt)
CZ (1) CZ20014289A3 (pt)
DE (1) DE60012745T2 (pt)
EE (1) EE200100647A (pt)
HK (1) HK1045814B (pt)
HU (1) HUP0201502A3 (pt)
IL (1) IL146407A0 (pt)
IS (1) IS6185A (pt)
MX (1) MXPA01012295A (pt)
NO (1) NO20015855L (pt)
NZ (1) NZ515317A (pt)
PL (1) PL352744A1 (pt)
RU (1) RU2252032C2 (pt)
SK (1) SK17392001A3 (pt)
TR (1) TR200103474T2 (pt)
TW (1) TWI243672B (pt)
WO (1) WO2000072838A1 (pt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1126838A4 (en) 1998-10-30 2005-02-16 Nitromed Inc NITROSIS AND NITROSYAL NON-STEROID ANTI-INFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE
US6852739B1 (en) 1999-02-26 2005-02-08 Nitromed Inc. Methods using proton pump inhibitors and nitric oxide donors
TWI243672B (en) * 1999-06-01 2005-11-21 Astrazeneca Ab New use of compounds as antibacterial agents
WO2001045703A1 (en) 1999-12-23 2001-06-28 Nitromed, Inc. Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use
SE0000774D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
CA2432642A1 (en) 2000-12-21 2002-08-08 Subhash P. Khanapure Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use
EP1219306A1 (en) * 2000-12-29 2002-07-03 Nicox S.A. Compositions comprising cyclodextrins and NO- releasing drugs
EA006398B1 (ru) 2001-06-01 2005-12-29 Поузен Инк. Фармацевтические композиции для координированной доставки нестероидных противовоспалительных лекарственных средств
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
SE0102993D0 (sv) 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system
US20040052928A1 (en) * 2002-09-06 2004-03-18 Ehud Gazit Peptides and methods using same for diagnosing and treating amyloid-associated diseases
US7781396B2 (en) * 2002-01-31 2010-08-24 Tel Aviv University Future Technology Development L.P. Peptides directed for diagnosis and treatment of amyloid-associated disease
EP1336602A1 (en) * 2002-02-13 2003-08-20 Giovanni Scaramuzzino Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
JP2006501161A (ja) * 2002-06-11 2006-01-12 ニトロメッド インク． ニトロソ化および／またはニトロシル化シクロオキシゲナーゼ−２選択的阻害剤、組成物ならびに使用方法
AU2003247792B2 (en) 2002-07-03 2009-09-24 Nicox S.A. Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use
CA2493156A1 (en) 2002-07-29 2004-02-05 Nitromed, Inc. Cyclooxygenase-2 selective inhibitors, compositions and methods of use
JP4634144B2 (ja) 2002-08-01 2011-02-16 ニコックス エスエー ニトロソ化プロトンポンプ阻害剤、組成物および使用方法
AU2003283096A1 (en) * 2002-11-05 2004-06-07 Merck Frosst Canada And Co. Nitric oxide releasing prodrugs of diaryl-2-(5h)-furanones as cyclooxygenase-2 inhibitors
US7491699B2 (en) * 2002-12-09 2009-02-17 Ramot At Tel Aviv University Ltd. Peptide nanostructures and methods of generating and using the same
EP1583713B1 (en) * 2003-01-07 2009-03-25 Ramot at Tel Aviv University Ltd. Peptide nanostructures encapsulating a foreign material and method of manufacturing same
SE0301880D0 (sv) * 2003-06-25 2003-06-25 Astrazeneca Uk Ltd New drug delivery composition
CA2530927A1 (en) 2003-06-30 2005-01-06 Tel Aviv University Future Technology Development L.P. Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases
US20050054714A1 (en) * 2003-07-17 2005-03-10 Benito Munoz Nitric oxide releasing drugs for Alzheimer's disease
JP4917889B2 (ja) 2003-09-25 2012-04-18 テル アヴィヴ ユニヴァーシティ フューチャー テクノロジー ディヴェロップメント エル．ピー． アミロイド関連疾患を処置するための組成物及びその使用方法
WO2005031362A2 (en) * 2003-10-02 2005-04-07 Ramot At Tel Aviv University Ltd. Novel antibacterial agents and methods of identifying and utilizing same
US8007847B2 (en) 2004-01-13 2011-08-30 Eytan Biderman Feeding formula appliance
US20090156471A1 (en) * 2004-07-15 2009-06-18 Ramot At Tel Aviv University Ltd. Use of anti-amyloid agents for treating and typing pathogen infections
EP1781310B1 (en) * 2004-08-02 2015-10-14 Ramot at Tel Aviv University Ltd. Articles of peptide nanostructures and method of forming the same
ATE539745T1 (de) 2004-08-19 2012-01-15 Univ Tel Aviv Future Tech Dev Zusammensetzungen zur behandlung von amyloid- assoziierten erkrankungen
WO2006027780A2 (en) 2004-09-08 2006-03-16 Ramot At Tel Aviv University Ltd. Peptide nanostructures containing end-capping modified peptides and methods of generating and using the same
ES2354278T3 (es) * 2005-07-26 2011-03-11 Nicox S.A. Formulación farmaceutica de nitroxiderivado de aines.
WO2007043048A2 (en) * 2005-10-11 2007-04-19 Ramot At Tel Aviv University Ltd. Self-assembled fmoc-ff hydrogels
US7879212B2 (en) * 2005-11-03 2011-02-01 Ramot At Tel-Aviv University Ltd. Peptide nanostructure-coated electrodes
JP2007275193A (ja) * 2006-04-04 2007-10-25 Fujifilm Corp 光プローブおよび光断層画像化装置
KR20110079641A (ko) 2008-09-09 2011-07-07 아스트라제네카 아베 제약 조성물을 이를 필요로 하는 환자에게 전달하는 방법
SG176724A1 (en) 2009-06-25 2012-01-30 Astrazeneca Ab Method for treating a patient at risk for developing an nsaid-associated ulcer
WO2012066549A1 (en) 2010-11-15 2012-05-24 Ramot At Tel-Aviv University Ltd. Dipeptide analogs for treating conditions associated with amyloid fibril formation
US9539214B2 (en) 2011-12-28 2017-01-10 Pozen Inc. Compositions and methods for delivery of omeprazole plus acetylsalicylic acid
CN104815330A (zh) * 2015-05-22 2015-08-05 杜林� 乙酸类非甾体抗炎药的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
IL75400A (en) 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
AU4640985A (en) 1984-08-31 1986-03-06 Nippon Chemiphar Co. Ltd. Benzimidazole derivatives
SE8804629D0 (sv) 1988-12-22 1988-12-22 Ab Haessle New therapeutically active compounds
IL98680A0 (en) 1991-06-30 1992-07-15 Yeda Res & Dev Hydroxamate derivatives and pharmaceutical compositions containing them
IT1256345B (it) * 1992-08-20 1995-12-01 Esteri nitrici di derivati dell'acido 2-(2,6-di-alo-fenilammino) fenilacetico e procedimento per la loro preparazione
IT1256450B (it) * 1992-11-26 1995-12-05 Soldato Piero Del Esteri nitrici con attivita' farmacologica e procedimento per la loro preparazione
SE9301830D0 (sv) 1993-05-28 1993-05-28 Ab Astra New compounds
SE9302396D0 (sv) 1993-07-09 1993-07-09 Ab Astra A novel compound form
HU218923B (hu) * 1993-10-06 2000-12-28 Nicox S.A. Gyulladásgátló és/vagy fájdalomcsillapító hatású nitrát-észterek, ezeket tartalmazó gyógyszerkészítmények és eljárás a vegyületek előállítására
AU7972294A (en) 1993-10-07 1995-05-01 Entremed, Inc Encapsulated and non-encapsulated nitric oxide generators used as antimicrobial agents
CA2190087C (en) * 1994-05-10 2005-08-02 Piero Del Soldato Nitro compounds and their compositions having anti-inflammatory, analgesic and anti-thrombotic activities
IT1282686B1 (it) * 1996-02-26 1998-03-31 Nicox Sa Composti in grado di ridurre la tossicita' da farmaci
US5785689A (en) 1996-07-18 1998-07-28 Act Medical, Inc. Endoscopic catheter sheath position control
WO1998022117A1 (en) * 1996-11-22 1998-05-28 The Procter & Gamble Company Compositions for the treatment of gastrointestinal disorders containing bismuth, and nsaid and one or more antimicrobials
US6207855B1 (en) 1998-06-23 2001-03-27 Duke University Medical Center Stable no-delivering compounds
TWI243672B (en) * 1999-06-01 2005-11-21 Astrazeneca Ab New use of compounds as antibacterial agents

Also Published As

Publication number Publication date
NO20015855D0 (no) 2001-11-30
HK1045814A1 (en) 2002-12-13
KR100671392B1 (ko) 2007-01-22
KR20020015334A (ko) 2002-02-27
SK17392001A3 (sk) 2002-07-02
BG106158A (en) 2002-06-28
AU5262300A (en) 2000-12-18
TWI243672B (en) 2005-11-21
CA2373653A1 (en) 2000-12-07
EP1196155A1 (en) 2002-04-17
WO2000072838A1 (en) 2000-12-07
ATE272396T1 (de) 2004-08-15
CA2373653C (en) 2011-03-15
CN1165298C (zh) 2004-09-08
HK1045814B (zh) 2005-04-01
HUP0201502A3 (en) 2003-03-28
TR200103474T2 (tr) 2002-04-22
EE200100647A (et) 2003-02-17
AU780678B2 (en) 2005-04-07
RU2252032C2 (ru) 2005-05-20
JP2003500442A (ja) 2003-01-07
DE60012745D1 (de) 2004-09-09
NZ515317A (en) 2004-05-28
AR024159A1 (es) 2002-09-04
CZ20014289A3 (cs) 2002-05-15
PL352744A1 (en) 2003-09-08
CN1354658A (zh) 2002-06-19
DE60012745T2 (de) 2005-09-15
HUP0201502A2 (en) 2002-08-28
US6593339B1 (en) 2003-07-15
IL146407A0 (en) 2002-07-25
US20040048917A1 (en) 2004-03-11
IS6185A (is) 2001-11-29
MXPA01012295A (es) 2002-07-30
NO20015855L (no) 2002-01-30
JP4818516B2 (ja) 2011-11-16
EP1196155B1 (en) 2004-08-04

Similar Documents

Publication Publication Date Title
BR0011116A (pt) Usos de uma nsaid que libera no como um sal farmaceuticamente aceitável ou um enanciÈmero do mesmo, e de uma nsaid que libera no e de um inibidor de bomba de próton suscetìvel a ácido ou um sal do mesmo ou um enanciÈmero ou de um sal do enanciÈmero, método para o tratamento de uma infecção bacteriana, e, formulação farmacêutica adequada para uso no tratamento de infecções bacterianas
CY1118059T1 (el) Συνθεσεις αντιλοιμωδων βασει λιπιδιων για αγωγη πνευμονικων λοιμωξεων
BR0013010A (pt) Formulação de cloreto de sódio de moxifloxacina
BR0209658A (pt) Derivados de 4-amino-5-fenil-7-1ciclobutil-pirrolo [2,3-d] pirimidina
NO20076083L (no) Mukoadhesive xyloglukaninneholdende formuleringer som er anvendelige i medisinske anordninger og i farmasoytiske formuleringer
DK0413528T3 (da) Amphotere præparater og polymere former af alphahydroxysyrer og deres terapeutiske anvendelse
BRPI0408999A (pt) comprimidos prensados de multiparticulados de liberação oral prolongada
BRPI0408559A (pt) composições farmacêuticas dispersìveis para o tratamento de mastite e distúrbios óticos
BR9908617A (pt) Nitroto inorgânico e ácido orgânico em combinação como uma composição antiviral tópica.
BRPI0415953A (pt) formulação de dosagem de liberação controlada oral, método de tratamento de um distúrbio, conjunto de formas de dosagem de liberação controlada e método para administração da formulação
BR0315337A (pt) Composto, formulação farmacêutica, e, método para tratar câncer
BR0306214A (pt) Composto de 4-oxoquinolina e uso deste como inibidor de integrase de hiv
BR0012590A (pt) Composto, processo para a preparação do mesmo, formulação farmacêutica, uso de um composto, e, métodos para tratamento ou profilaxia de dor ou desconforto, e para tratamento ou profilaxia de dor neuropática ou central
BR0000003A (pt) Azalidas e métodos de preparação das mesmas
BRPI0508933A (pt) composições para entrega tópica
PT914110E (pt) Metodo de modulacao da micro-circulacao
BR9807319A (pt) Microgrânulos com liberação controlada, para administração oral, contendo cisplatina, processo de preparação dos mesmos, preparação farmacêutica, e, utilização dos microgrânulos.
BR9812553A (pt) Formulação medicamentosa com liberação de substância ativa controlada
DK1383752T3 (da) Deutererede 3-piperidinopropiophenoner samt lægemidler indeholdende disse forbindelser
BRPI0416376A (pt) composições para a redução da colonização bacteriana e da invasão do snc e métodos de uso destes
BRPI0414305A (pt) sistema de liberação de drogas por via oral
CA2504872A1 (en) Use of resveratrol for the preparation of a medicament useful for the treatment of influenza virus infections
BR0111933A (pt) Uso de ácido pamÈico ou um de seus derivados, ou um de seus análogos, para a preparação de um medicamento para o tratamento de doenças caracterizadas por depósitos de agregados amilõides
BR0006301A (pt) Macrólidos antibacterianos e pró-cinéticos
BR0011880A (pt) Método para o tratamento de condições co-mórbidas associadas com obesidade, composto, produto, uso de um composto, e, composição farmacêutica

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: NICOX S.A. (FR)

Free format text: TRANSFERIDO DE: ASTRAZENECA AB

B25G Requested change of headquarter approved

Owner name: NICOX S.A. (FR)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020070016104/RJ DE 07/02/2007.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 10( VIII ),13, 24 E 25 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.